Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.45 |
| ▸ | TNF | P01375 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 2/20 | 0.35 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | HTR1F | P30939 | 2/20 | 0.35 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | TNFSF11 | O14788 | 5/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120066 | 0.88 | HTR6 (0.41) | HTR6TNF | |
| SCHEMBL16100482 | 0.85 | HTR6 (0.46) | HTR6HTR1AHTR1DHTR1BHTR1F | |
| SCHEMBL17457571 | 0.80 | HTR6 (0.36) | HTR6 | |
| SCHEMBL16102368 | 0.75 | HTR6 (0.43) | HTR6HTR1AHTR1DHTR1BESR2 | |
| SCHEMBL16100818 | 0.73 | HRH1 (0.41) | HTR6 | |
| SCHEMBL17457568 | 0.72 | MAPT (0.35) | HTR6 | |
| SCHEMBL16099896 | 0.69 | HTR6 (0.42) | HTR6ESR2 | |
| SCHEMBL17457582 | 0.69 | HTR2A (0.38) | HTR1A | |
| SCHEMBL17457570 | 0.65 | MAPT (0.35) | — | |
| SCHEMBL3040501 | 0.63 | IDE (0.55) | HTR6IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765035-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024017-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | HTR6 2832/4885TNF 4795/4885HTR1A 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.